Eli Lilly’s obesity drug Zepbound led to nearly 50 percent more weight loss than Novo Nordisk’s Wegovy in the first direct ...

Eli Lilly and Company (NYSE:LLY) is a leading medicine company which discovers, develops, manufactures, and markets products ...

It has been corrected. A study of two blockbuster weight-loss drugs showed that users of Eli Lilly’s Zepbound lost just over 2 inches more off their waists compared with Novo Nordisk’s rival ...

Though Eli Lilly and Novo Nordisk have recently taken steps to make their uber-popular GLP-1 drugs more affordable for ...

While the early week buzz centered around the U.S.-China trade agreement, another critical development unfolded quietly but ...

Derived prices are not provided by exchanges. They are derived by market makers in CFD OTC market and hence prices may not be accurate and may differ from the actual market price, meaning prices ...

Lilly and AZ have a rival in the BACE field – Merck's MK-8931 is currently in a phase 2/3 study treating patients with mild to moderate Alzheimer's. BACE offers hope ...